Australia - English - Department of Health (Therapeutic Goods Administration)

stryker australia pty ltd -

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

gulf drug company (pty) ltd - injection - each vial contains cefuroxime sodium equivalent to cefuroxime 750,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

gulf drug company (pty) ltd - injection - each vial contains cefuroxime sodium equivalent to cefuroxime 1,5 g

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

gulf drug company (pty) ltd - injection - each vial contains cefotaxime sodium equivalent to cefotaxime 1,0 g

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

gulf drug company (pty) ltd - injection - each vial contains cefotaxime sodium equivalent to cefotaxime 2,0 g

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadodiamide, quantity: 287 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; caldiamide sodium hydrate; water for injections; sodium hydroxide - other conditions: do not freeze. omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood brain barrier or abnormal vascularity. indications as at 10 december 1999: omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity and whole body imaging. indications as at 25 june 2003: omniscan is indicated for: 1) use in adults and children, including infants and neonates less than 6 months of age for the enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity, and; 2) whole body imaging for adults and children over 6 months of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadodiamide, quantity: 287 mg/ml - injection, solution - excipient ingredients: caldiamide sodium hydrate; water for injections; sodium hydroxide; hydrochloric acid - other conditions: do not freeze. omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood brain barrier or abnormal vascularity. indications as at 10 december 1999: omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularlity and whole body imaging. indications as at 25 june 2003: omniscan is indicated for: 1) use in adults and children, including infants and neonates less than 6 months of age for the enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity, and; 2) whole body imaging for adults and children over 6 months of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadodiamide, quantity: 287 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide; caldiamide sodium hydrate - other conditions: do not freeze. omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood brain barrier or abnormal vascularity. indications as at 10 december 1999: omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity and whole body imaging. indications as at 25 june 2003: omniscan is indicated for: 1) use in adults and children, including infants and neonates less than 6 months of age for the enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity, and; 2) whole body imaging for adults and children over 6 months of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadodiamide, quantity: 287 mg/ml - injection - excipient ingredients: caldiamide sodium hydrate; sodium hydroxide; water for injections; hydrochloric acid - omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity and whole body imaging. indications as at 25 june 2003: omniscan is indicated for: 1) use in adults and children, including infants and neonates less than 6 months of age for the enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity, and; 2) whole body imaging for adults and children over 6 months of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadodiamide, quantity: 287 mg/ml - injection - excipient ingredients: water for injections; caldiamide sodium hydrate; sodium hydroxide; hydrochloric acid - omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity and whole body imaging. indications as at 25 june 2003: omniscan is indicated for: 1) use in adults and children, including infants and neonates less than 6 months of age for the enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity, and; 2) whole body imaging for adults and children over 6 months of age.